Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

709 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Potent and biostable inhibitors of the main protease of SARS-CoV-2.
Tsuji K, Ishii T, Kobayakawa T, Higashi-Kuwata N, Azuma C, Nakayama M, Onishi T, Nakano H, Wada N, Hori M, Shinohara K, Miura Y, Kawada T, Hayashi H, Hattori SI, Bulut H, Das D, Takamune N, Kishimoto N, Saruwatari J, Okamura T, Nakano K, Misumi S, Mitsuya H, Tamamura H. Tsuji K, et al. Among authors: mitsuya h. iScience. 2022 Nov 18;25(11):105365. doi: 10.1016/j.isci.2022.105365. Epub 2022 Nov 1. iScience. 2022. PMID: 36338434 Free PMC article.
Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan.
Terada-Hirashima J, Takamatsu Y, Shimizu Y, Uemura Y, Takeuchi JS, Tomita N, Matsuda K, Maeda K, Yamamoto S, Fukunaga A, Ohmagari N, Mikami A, Sonoda K, Ujiie M, Mitsuya H, Sugiura W. Terada-Hirashima J, et al. Among authors: mitsuya h. Hum Vaccin Immunother. 2023 Dec 31;19(1):2193074. doi: 10.1080/21645515.2023.2193074. Epub 2023 Apr 13. Hum Vaccin Immunother. 2023. PMID: 37052247 Free PMC article. Clinical Trial.
Exploration of imatinib and nilotinib-derived templates as the P2-Ligand for HIV-1 protease inhibitors: Design, synthesis, protein X-ray structural studies, and biological evaluation.
Ghosh AK, Mishevich JL, Kovela S, Shaktah R, Ghosh AK, Johnson M, Wang YF, Wong-Sam A, Agniswamy J, Amano M, Takamatsu Y, Hattori SI, Weber IT, Mitsuya H. Ghosh AK, et al. Among authors: mitsuya h. Eur J Med Chem. 2023 Jul 5;255:115385. doi: 10.1016/j.ejmech.2023.115385. Epub 2023 Apr 21. Eur J Med Chem. 2023. PMID: 37150084 Free PMC article.
Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial.
Saito S, Kutsuna S, Akifumi I, Hase R, Oda R, Terada J, Shimizu Y, Uemura Y, Takamatsu Y, Yasuhara A, Shiratori K, Satake M, Sakamoto N, Miyazaki Y, Shimizu H, Togano T, Matsunaga A, Okuma K, Hamaguchi I, Fujisawa K, Nagashima M, Ashida S, Terada M, Kimura A, Morioka S, Matsubayashi K, Tsuno NH, Kojima M, Kuramitsu M, Tezuka K, Ikebe E, Ishizaka Y, Kenji M, Hangaishi A, Mikami A, Sugiura W, Ohmagari N, Mitsuya H. Saito S, et al. Among authors: mitsuya h. J Infect Chemother. 2023 Sep;29(9):869-874. doi: 10.1016/j.jiac.2023.05.012. Epub 2023 May 11. J Infect Chemother. 2023. PMID: 37178973 Free PMC article. Clinical Trial.
Synthesis of novel entecavir analogues having 4'-cyano-6''-fluoromethylenecyclopentene skeletons as an aglycone moiety as highly potent and long-acting anti-hepatitis B virus agent.
Kumamoto H, Higashi-Kuwata N, Hayashi S, Das D, Bulut H, Tokuda R, Imoto S, Onitsuka K, Honda Y, Odanaka Y, Shimbara-Matsubayashi S, Haraguchi K, Tanaka Y, Mitsuya H. Kumamoto H, et al. Among authors: mitsuya h. RSC Adv. 2023 May 31;13(23):15999-16011. doi: 10.1039/d3ra01750h. eCollection 2023 May 22. RSC Adv. 2023. PMID: 37265996 Free PMC article.
709 results